Was JNJ Stock Rally Actually Its Own?

Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.

Johnson & Johnson Lost More Than Half Of STELARA And Still Grew

STELARA sales fell 55.7% in Q2 2026 as biosimilars took share, a drag of roughly 460 basis points on the whole company’s growth. Johnson & Johnson still reported operational sales growth of 5.6% in the quarter, and management said that excluding STELARA the company grew double digits. TREMFYA, the immunology drug it is pushing into ulcerative colitis and Crohn’s disease, grew 71%.

Management raised the full-year 2026 operational sales outlook to 6.5% to 7.1% – a midpoint of $100.6 billion – growth that includes about 100 basis points from a 53rd week in the financial calendar. The company is on track, it says, to pass $100 billion of annual revenue for the first time in its 140-year history.

So What Else Was Doing The Lifting?

Revenue over the trailing twelve months is $97.93 billion, up 8.1% year over year, against a three-year average of 6.0%. That acceleration is real, and small. Reported profitability went the other way: net margin sits at 21.5% against a three-year average of 29.4%. That baseline, however, was heavily skewed by below-the-line items—primarily the one-off gain from the Kenvue separation—which is why the historical net margin sits above the three-year average operating margin of 25.7%. With operating margin currently running at 26.8%, core business profitability has held steady; the apparent margin drop reflects normalization after that windfall, not operational erosion.

The operating news was not uniformly good either. Abiomed sales fell 2% in Q2 2026 after a neutral clinical trial in the U.K. on high-risk PCI made physicians more cautious about using its Impella pumps, and management expects the rebound to arrive as 2026 turns into 2027.

The rest of the sector also had a good year. Merck returned 87.0% over the same window and Eli Lilly 58.2%, though Pfizer managed 24.4%, so the market paid up for large-cap pharma selectively, and Johnson & Johnson was not the only name it paid for.

You Are Still Waiting For The Talc Agreement To Close

One development over these twelve months was Johnson & Johnson’s alone. In late July 2026, it announced a proposed $5.5 billion settlement framework aimed at resolving the vast majority of pending ovarian cancer talc claims. That is company-specific in a way the peer returns are not. It is also not finished.

The agreement is conditioned, among other things, on the express participation of at least 95% of the remaining claims. A month after it was announced, a Louisiana jury returned a $10 million verdict in a separate talc-related mesothelioma case, in which Johnson & Johnson’s apportioned share was over $1.2 million. Meanwhile, whether the ovarian agreement holds will hinge on reaching that 95% participation threshold. A different question is whether management has room to keep pushing its outlook higher, and our screen for guidance-driven momentum shows which companies keep raising their own numbers.

Enjoy The Move, Then Check What It Did To Your Allocation

A move like this is even better to own than to watch, and it is also how one holding grows into an outsized share of a portfolio. Concentration tends to arrive by accident rather than by decision. What your largest position would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.